Extended follow-up of this pivotal phase II trial suggests 3-month response to axi-cel may be prognostic of long-term remissions.
Ivosidenib produced durable responses in heavily pretreated patients with relapsed/refractory IDH1-mutated AML.
This CD22-targeted antibody–drug conjugate induced deep and durable responses in a heavily pretreated patient population with HCL.
Preliminary findings suggest venetoclax plus decitabine or azacitidine is well tolerated with deep, durable responses in elderly patients with previously untreated AML.
Retrospective analysis suggests that sequential use of blinatumomab and HSCT may benefit patients with BCP-ALL, particularly in younger patients.
Lenalidomide plus rituximab did not improve CR rate or PFS over chemotherapy plus rituximab but was associated with lower rates of neutropenia and febrile neutropenia.
Acalabrutinib monotherapy yielded a 93% ORR across cohorts with durable responses and a favorable safety profile.
Early results show promising clinical responses and MRD clearance with combination first-line treatment in CLL with ibrutinib and venetoclax.
Median PFS and ORR significantly improved with once- vs twice-weekly dosing of carfilzomib + dexamethasone in patients with relapsed/refractory multiple myeloma.
The addition of pomalidomide to bortezomib and low-dose dexamethasone extends PFS vs bortezomib and low-dose dexamethasone alone in patients with relapsed/refractory multiple myeloma who have previously received lenalidomide.
Daratumumab with carfilzomib and dexamethasone was well tolerated and active in patients with lenalidomide-refractory relapsed multiple myeloma.
Planned interim analysis of phase III iNNOVATE study shows significant improvements in PFS with ibrutinib plus rituximab vs rituximab alone in patients with Waldenström macroglobulinemia.
VenKd was well tolerated with promising response rates in R/R MM, including both high-risk and standard-risk patients, in a phase II trial.
At active doses, bb2121 induced deep responses independent of BCMA expression and was associated with predominantly low-grade and manageable toxicities.
Twice-weekly 56-mg/m2 carfilzomib showed similar PFS and OS but higher VGPR rate vs 27-mg/m2 carfilzomib in patients with relapsed/refractory multiple myeloma.